Objective: Inter polyelectrolyte complexes (IPECs) are an emerging biocompatible polymeric carrier system to transport active substances at target sites. The aim of this study was to evaluate the use of hydrophobic waxy retardant polymer glyceryl monooleate in hydrophilic inter polyelectrolyte matrix system containing three principal anti-tubercular drugs (ATDs). Sustained release polymeric matrix system was prepared by melt granulation technique, which allowed for the manufacture of the multi-layered tablets for segregated delivery of rifampicin, isoniazid and pyrazinamide. Material and methods: The matrix system consisting of hydrophilic IPEC of chitosan and carboxymethyl guar gum in combination with hydrophobic waxy retardant polymer, prepared by melt granulation technique was found to achieve segregated delivery of rifampicin, isoniazid and pyrazinamide. The applicability of piperine, an organic alkaloid as bio enhancer and rifampicin-sodium lauryl sulphate (SLS) complex was tested for improvement in bioavailability of antituberculosis fixed dose combination (FDC), lowering dosage levels and shortening the treatment course. Results: There was no incompatability observed between drug and excipeints based upon FTIR, DSC and X-RD studies. The optimized tablet (composition IPEC 46 % w/w (275mg), glyceryl monooleate 2 % w/w (11.5mg), piperine 1 % w/w (5 mg), pyrazinamide (150mg), isoniazid (50mg) and rifampicin-SLS complex (95.2mg) sustained the delivery of drugs for 12 h. IPECs alone lack sufficient mucoadhesion hence, suitable combination of polymeric blends along with IPEC played a key role in controlling the initial burst release pattern, desired bioadhesion (14.25g) and swelling index (1248.8%). Conclusion: This biocompatible, biodegradable and naturally renewable polymeric matrix system could be successfully utilized in a FDC to maximally release ATDs in a sustained manner achieving complete dissolution.
Cite this article:
Prasanthi Boddu, Vijaya Ratna Jayanti. Glyceryl Monooleate Functionalized Matrix with an Inter Polyelectrolyte Complex System for the Management of Drug Resistance in Tuberculosis. Research J. Pharm. and Tech. 2020; 13(10):4839-4850. doi: 10.5958/0974-360X.2020.00852.5
Prasanthi Boddu, Vijaya Ratna Jayanti. Glyceryl Monooleate Functionalized Matrix with an Inter Polyelectrolyte Complex System for the Management of Drug Resistance in Tuberculosis. Research J. Pharm. and Tech. 2020; 13(10):4839-4850. doi: 10.5958/0974-360X.2020.00852.5 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-10-55
1. Blomberg B, Spinaci S, Fourie B, Laing R, The rationale for recommending fixed dose combination tablets for treatment of tuberculosis, Bull WHO, 2001; 79: 1.
2. Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, et al. Fixed-dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective, Methods Find Exp Clin Pharmacol, 2004; 26: 703-21.
3. Bhutani H, Mariappan TT, Singh S, A study on the physical and chemical stability of anti-tuberculosis fixed-dose combination (FDC) products under accelerated climatic conditions, Int J Tuber Lung Dis, 2004; 8: 1073-80.
4. Prasanthi B, Prasanthi D, Bhavani B, Vijaya Ratna J, Formulation development and evaluation of novel drug delivery system of anti-tubercular drugs, Int J Pharmacy, 2014; 4: 189-96.
5. Qurrat ul-Ain, Sadhna Sharma, Khuller GK, Chemotherapeutic potential of orally administered poly (lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis, Antimicrob Agents Chemother, 2003; 47: 3005-07.
6. Prabhakaran D, Singh P, Jaganathan KS, Vyas SP, Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of antitubercular drugs, J Control Release, 2004; 95: 239-48.
7. Pandey R and Khuller GK, Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers, J Antimicrob Chemoth, 2004; 53: 635-40.
8. Vinsova J and Vavrikova E, Recent advances in drugs and prodrugs design of chitosan, Curr Pharm Design, 2008; 14: 1311-26.
9. Becker C, Dressman JB, Junginger HE, et al. Bio waiver monographs for immediate release solid oral dosage forms: Rifampicin, J Pharm Sci, 2009; 98: 2252–67.
10. Becker C, Dressman JB, Amidon GL, et al. Bio waiver monographs for immediate release solid oral dosage forms: Isoniazid, J Pharm Sci, 2007; 96: 522–31.
11. Becker C, Dressman JB, Amidon GL, et al. Bio waiver monographs for immediate release solid oral dosage forms: Pyrazinamide, J Pharm Sci, 2008; 97: 3709–20.
12. Lankalapalli S and Kolapalli RM, Polyelectrolyte complexes: A review of their applicability in drug delivery technology. Ind J Pharm Sci. 2009; 71: 481-87.
13. Vogel MK, Cross RA, Bixler HJ, Gujman RJ. Medical uses of polyelectrolyte complexes. J Macromol Sci Chem. 1970; 4: 675-92.
14. Vimal Kumar Yadav, A.B. Gupta, Raj Kumar, Jaideep S. Yadav, Brajesh Kumar. Mucoadhesive Polymers: Means of Improving the Mucoadhesive Properties of Drug Delivery System. J. Chem. Pharm. Res. 2010; 2: 418-32.
15. Santhosh S, Sini TK, Anandan R, Mathew PT, Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats, Eur J Pharmacol, 2007; 572: 69–73.
16. Saleh M Al-Saidan, Yellela SR Krishnaiah, Patro S, Vemulapalli Satyanaryana, In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride, AAPS Pharm Sci Tech, 2005; 6: E14-21.
17. Muranishi S, Modification of intestinal absorption of drugs by lipoidal adjuvants, Pharm Res, 1985; 2: 108–18.
18. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller, Prasasd B. J, Antimicrob Chemoth, 2003; 52: 981-86.
19. Mukesh C G, Krishnakant G S, A Novel solid dosage form of rifampicin and isoniazid with improved functionality, AAPS Pharm Sci Tech, 2007; 8: E1-E7.
20. La ise Adriane Hegeto, Katiany R. Caleffi-Ferracioli, Sandra S. Nakamura-Vasconcelos, Aryadne Larissa de Almeida, Vanessa Pietrowski Baldin, Celso Vataru Nakamura, et al., In vitro combinatory activity of piperine and anti-tuberculosis drugs in mycobacterium tuberculosis. Tuberculosis, 2018: 111: 35-40.
21. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB, Stability of rifampicin in dissolution medium in presence of isoniazid, Int J Pharm, 1999; 190: 109-23.
22. Kramarenko EY, Khokhlov AR, Reineker P, Stoichiometric polyelectrolyte complexes of ionic block copolymers and oppositely charged polyions, J Chem Phys, 2006; 125: 1–8.
23. Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, 11th ed. Merck and Col., 1989.
24. Prasanthi B, Mohan Varma M, Vijaya Ratna J, Development of dissolution medium for rifampicin, isoniazid and pyrazinamide fixed-dose formulation, Int J Adv Pharm Res, 2014; 5: 208-18.
25. Parodi B, Russo E, Caviglioli G, Cafaggi S, Bignardi G, Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride, Drug Dev Ind Pharm, 1996; 22: 445-50.
26. Bromberg L, Temchenko M, Alakhov V, Hatton TA, Bioadhesive properties and rheology of polyether-modified poly (acrylic acid) hydrogels, Int J Pharm, 2004; 282: 45-60.
27. Satish Balkrishna Bhise and Sevukarajan Mookkan, Formulation and evaluation of novel FDCs of antitubercular drugs, J Pharm Res, 2009; 2: 437-44.
28. Singh S, Mariappan TT, Sankar R, et al. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem, Int J Pharm, 2001; 228: 5–17.
29. Narayan Bhattarai, Jonathan Gunn, Miqin Zhang, Chitosan-based hydrogels for controlled, localized drug delivery, Adv Drug Del Review, 2010; 62: 83–99.
30. Geoffroy JM, Fredrickson JK, Shelton JT, A mixture of experiment approach for controlling the dissolution rate of a sustained release tablet, Drug Dev Ind Pharm, 1998; 24: 799-06.
31. Hamed E, Sakr A, Application of multi response optimization technique to extend release formulation design, J Control Rel, 2001; 73: 329-38.